Ronin Capital and SW Investment Nominees background and qualifications:
Gregory P. Sargen: Mr. Gregory P. Sargen has been Executive Vice President of Corporate Development & Strategy at Cambrex Corporation since January 20, 2017. Mr. Sargen served as the Chief Financial Officer of Cambrex Corporation from February 9, 2007 to January 20, 2017 and its Executive Vice President from January 2011 to January 20, 2017 and also served as its Principal Accounting Officer until January 20, 2017. Mr. Sargen served as Vice President of Cambrex Corporation. since February 2007 and also served as its Vice President of Finance. Mr. Sargen has rare combination of broad financial experience, excellent business acumen and strong leadership skills. Mr. Sargen served as Vice President of Finance at Cambrex Corporation. since February 2003. He served as an Executive Vice President for Finance, Chief Financial Officer, Vice President and Corporate Controller of Exp@nets, Inc. from 1999 to 2002. From 1996 to 1998, he served as Vice President of Finance and Controller of Fischer Scientific International's Chemical Manufacturing Division. Mr. Sargen held various positions in finance, accounting and audit with Merck & Company, Inc., Heat and Control, Inc., and Deloitte & Touche. Mr. Sargen holds an MBA degree from the Wharton School of Business. Mr. Sargen is a Certified Public Accountant
Brian W. Scanlan: Experience
•
Managing Partner
Company Name Freedom Bioscience Partners
Dates Employed2015 – Present
Employment Duration 2 yrs
Board of directors and C-Suite pharmaceutical services business advisory firm providing direct, dedicated senior leadership support, strategic direction and industry expertise to define opportunities, augment M&A transactions, create strategic sales and growth plans, enhance/develop sales teams, install infrastructure and build capabilities.
Operate in senior executive, board advisory and interim executive roles to drive revenue growth and maximize enterprise value: business development, global sales team development. Also operate as key partner to Private Equity and Investment Banking community providing M&A and portfolio company support, developing growth narrative, crisis management, and energizing top line growth.
•
Board of Trustees
Company NameThe Leukemia & Lymphoma Society
Dates EmployedJun 2011 – Jun 2015
Employment Duration4 yrs 1 mo
LocationWisconsin Chapter
The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
•
Board of Governors
Company NameSOCMA
Dates EmployedDec 2013 – Jun 2014
Employment Duration7 mos
SOCMA, the Society of Chemical Manufacturers and Affiliates, Inc., is the only U.S. based trade association dedicated solely to the batch, custom and specialty chemical industry. From its office in Washington, DC, SOCMA advocates for U.S. laws and regulations that affect our members' competitiveness and bottom line.
Today, SOCMA member companies encompass every segment of the industry and manufacture tens of thousands products annually that are valued at $24 billion. The industry’s impact on U.S. GDP is upwards of $2.9 trillion.
•
Member Board of Directors
Company NameCambridge Major Laboratories, Inc.
Dates Employed2007 – Jun 2014
Employment Duration7 yrs
Cambridge Major Laboratories, Inc. and AAIPharma Services Corp. have joined to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With nearly 800 employees operating out of seven sites in the US and Europe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services.
•
President and CEO (API Development, API Manufacturing, Drug Development)
Company NameCambridge Major Laboratories
Dates EmployedMar 2011 – Nov 2013
Employment Duration2 yrs 9 mos
Cambridge Major Laboratories, Inc. (CML) is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. The Company produces pharmaceutical intermediates and Active Pharmaceutical Ingredients (API), from early preclinical development to commercial manufacture. Operating from FDA inspected facilities in the US and Europe, CML is organized along five key Centers of Excellence including; Process Chemistry, GMP Manufacturing, Solid State Chemistry, Analytical Services, and Quality/Regulatory Compliance. Visit us at www.c-mlabs.com.
Specialties:API Developoment,API Manufacture,Drug Development,Active Pharmaceutical Ingredients,Solid State Chemistry,Analytical Chemistry,Process Development,preclinical,clinical trials,commercial,commercial API manufacture
See more positions
Education
•
Illinois Institute of Technology
Degree NameMBA
Field Of StudyMarketing
Dates attended or expected graduation1992 – 1995
executive MBA program focused on marketing and sales strategy
•
Northern Illinois University
Degree NameBachelors of Science
Field Of StudyChemistry
Dates attended or expected graduation1989 – 1991
Activities and Societies: Undergraduate Research Assistant
Chemistry, undergraduate research
Volunteer Experience
•
Committee Chair
Company NameBoy Scouts of America
Dates volunteeredMar 2016 – Present
Volunteer duration1 yr 6 mos
•
Middle School Youth Leader
Company NameLumen Christi
Dates volunteeredJan 2014 – Apr 2015
Volunteer duration1 yr 4 mos
CauseChildren
Saiid Zarrabian: Mr. Saiid Zarrabian serves as an Advisor of Redline Capital Partners, S.A. and Redline Capital Management S.A. Mr. Zarrabian served as Chief Executive Officer and President of Cyntellect Inc. from June 2010 to May 2012. He served as Vice President and an Officer of Symbolics Inc., was responsible for development, marketing and consulting services. He served as an Acting Chief Executive Officer of Cyntellect Inc., since March 2010. He served as President of the Protein Production Division of Intrexon Corporation. He served as Chief Operating Officer of Molecular Simulations and Symbolics, Inc. He served as R&D Director at Computervision, Inc. He also has over 30 years of senior executive or board member experience for multiple public and private companies, culminating in the creation of more than three billion dollars of shareholder value. He served as the Chief Operating Officer and MSI President of Accelrys Inc. He served as the President and Chief Operating Officer of Synomyx. He served as the Chief Operating Officer of Pharmacopeia. He served as President and Chief Operating Officer of Senomyx, Inc. He served as Chief Executive Officer and President of Molecular Simulations. He has performed executive consulting services for a variety of small- to mid-sized companies including BioBlocks, eMolecules, Invitrogen and SciTegic, where he served as Executive Consultant and acting Chief Operating Officer. He has more than 18 years of experience in high technology management, including product development for the CAD/CAM, software engineering and artificial intelligence markets. He served as the Chairman of the Board of La Jolla Pharmaceutical Co. from October 14, 2013 to August 2014. He has been a Director of DelMar Pharmaceuticals, Inc. since July 11, 2017. He serves as a Director of Chemistry eCommerce portal and eMolecules, Inc. He served as a Director of Immune Therapeutics, Inc. since September 25, 2015 until December 29, 2015. He served as a Director of Ambit Biosciences Corporation until December 19, 2012. He served as Independent Director of La Jolla Pharmaceutical Co. from January 2012 to August 19, 2015. He served as a Director of Cyntellect Inc. until 2012. He served as a Director of Exemplar Pharma, LLC. He served as a Director of Penwest Pharmaceuticals Co. from June 2010 to September 20, 2010. Mr. Zarrabian served as a Board Mem
